Wird geladen...
Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
Patients with metastatic or unresectable (advanced) pheochromocytoma and paraganglioma (PPGL) have poor prognoses and few treatment options. This multicenter, phase 2 trial evaluated the efficacy and safety of high-specific-activity (131)I-meta-iodobenzylguanidine (HSA (131)I-MIBG) in patients with...
Gespeichert in:
| Veröffentlicht in: | J Nucl Med |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Society of Nuclear Medicine
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6495236/ https://ncbi.nlm.nih.gov/pubmed/30291194 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.118.217463 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|